|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM251341283 |
| 003 |
DE-627 |
| 005 |
20231224161802.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.07.010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0837.xml
|
| 035 |
|
|
|a (DE-627)NLM251341283
|
| 035 |
|
|
|a (NLM)26222310
|
| 035 |
|
|
|a (PII)S1521-6616(15)30013-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Hong-Na
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.12.2015
|
| 500 |
|
|
|a Date Revised 24.09.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Pulsed low-dose cyclophosphamide (CTX) therapy has become a very effective approach in improving the clinical outcomes of lupus nephritis (LN) patients. However, variations of CTX therapeutic outcomes in LN patients are incompletely understood. We investigated the contributions of known allelic variants to CTX therapy outcomes in 77 LN patients. Then, 22 out of the 77 patients were randomly enrolled to evaluate the pharmacokinetic profiles. LN patients with a GSTA1*A mutation (CT heterozygous) had more risk of non-remission (44% vs. 20%, P=0.005). Pharmacokinetic data indicated that patients with a GSTA1*A heterozygous variant had a lower exposure to 4-hydroxycyclophosphamide (4OHCTX) compared to wild-type patients (AUC4OHCTX: 12.8 (9.8, 19.5) vs. 27.5 (18.1, 32.8) h mg/l, P=0.023). Clinical remission was significantly related to higher exposure of 4OHCTX (P=0.038). In conclusion, LN patients with GSTA1*A heterozygous genotypes had poor CTX treatment remission due to less exposure to activated metabolites of CTX
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cyclophosphamide
|
| 650 |
|
4 |
|a GSTA1
|
| 650 |
|
4 |
|a Lupus nephritis
|
| 650 |
|
4 |
|a Pharmacogenomics
|
| 650 |
|
4 |
|a Pharmacokinetics
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a 4-hydroxycyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 1XBF4E50HS
|2 NLM
|
| 650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
| 650 |
|
7 |
|a GSTA1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.5.1.18
|2 NLM
|
| 650 |
|
7 |
|a Glutathione Transferase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.5.1.18
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Xiao-Ye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Qiong-Hong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lai, Lin-Yun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Miao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yuan-Cheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hao, Chuan-Ming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Yong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Shan-Yan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 160(2015), 2 vom: 21. Okt., Seite 342-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:160
|g year:2015
|g number:2
|g day:21
|g month:10
|g pages:342-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.07.010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 160
|j 2015
|e 2
|b 21
|c 10
|h 342-8
|